Etcembly emerged from stealth mode in August with something it regards as seemingly impossible: A machine learning platform that has the ability to predict and engineer – at never-seen-before scale and speed – T-cell receptors (TCR) that enable bispecific T-cell engager antibodies targeting cancer cells to be produced. Read More
Pathogenic variants in the leucine-rich repeat kinase 2 (LRRK2) gene are linked to increased risk for Parkinson’s disease (PD), with G2019S being the principal variant. In the current study, researchers from Escape Bio Inc. presented the discovery and preclinical characterization of novel inhibitors of G2019S mutant-LRRK2 as potential therapeutic candidates for the treatment of PD. Read More
Beigene Ltd. and Ensem Therapeutics Inc. have announced an agreement for Beigene to acquire an exclusive global license to an IND application-ready oral cyclin-dependent kinase 2 (CDK2) inhibitor. Read More
Xinthera Inc. has disclosed tricyclic poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer. Read More
Abionyx Pharma SA has released new preclinical efficacy results with CER-001 after a single intraocular administration in a uveitis model with severe inflammation. Read More
Myricx Bio (Myricx Pharma Ltd.) and Wuxi Biologics Co. Ltd. have entered into a license agreement under which Myricx will have exclusive access to a proprietary antibody that was discovered based on Wuxi Bio's integrated technology platforms. Read More
REV-ERBα (NR1D1) is a circadian transcriptional repressor that plays a role in the regulation of lipid metabolism and macrophage function, and the global deletion of REV-ERBα has been previously linked to increased microglial activation and mitigation of amyloid plaque formation. In the current study, researchers from Washington University in St Louis and affiliated organizations aimed to explore the cell-autonomous effects of microglial REV-ERBα on tau pathology. Read More
Medshine Discovery Inc. has synthesized mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer. Read More
Tarapeutics Science Inc. has identified phosphatidylinositol 3-kinase δ (PI3Kδ) inhibitors reported to be useful for the treatment of cancer, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease (COPD) and systemic lupus erythematosus. Read More
CVI Pharmaceuticals has presented preclinical data on their thyroid hormone receptor beta (THRB) selective agonist CVI-2742 for the potential treatment of NASH. Selective activation of the THRB contributes to ameliorating the symptoms of nonalcoholic steatohepatitis (NASH), such as liver inflammation and fibrosis, hepatocyte ballooning and liver steatosis. Read More
Nippon Shinyaku Co. Ltd. has divulged discoidin domain-containing receptor 1 (DDR1) inhibitors reported to be useful for the treatment of nephritis. Read More
Tsinghua University has described non-structural protein 3 (nsp3; PL-pro) (SARS-CoV) inhibitors reported to be useful for the treatment of coronavirus acute respiratory syndrome. Read More
Researchers from RudaCure Co. Ltd. have presented preclinical efficacy data of RC-0165 as a potential treatment for osteoarthritis (OA) pain. Read More
Medigene AG has announced a prioritization of its pipeline as it advances its differentiated T-cell receptor engineered T cell (TCR-T) therapies for solid tumors. Read More
